The effect of HS-111, a novel thiazolamine derivative, on apoptosis and angiogenesis of hepatocellular carcinoma cells

Archives of Pharmacal Research
Myung-Joo ChoiSoon-Sun Hong

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies, yet there have been no significant advances in effective therapeutics. In this study, HS-111 was synthesized as a novel thiazolamine derivative, N-(5-(2-chlorobenzyl) thiazole-2-yl) benzofuran-2-carboxamide, and its anticancer effect and mechanism were examined in human HCC cells. HS-111 strongly suppressed the growth of HCC cells in a dose-dependent manner. Also, apoptosis by HS-111 was identified by DAPI and TUNEL staining, and the increases of the cleaved caspase-3 were observed. In addition, HS-111 decreased protein expression of hypoxia-inducible factor (HIF-1α) and secretion of vascular endothelial growth factor (VEGF), and inhibited tube formation and the migration of human umbilical vein endothelial cells (HUVECs). These results showed that HS-111 not only inhibited cell growth and angiogenesis, but also induced apoptosis of human HCC cells. We suggest that HS-111 may be a potential candidate for chemotherapy against HCC.

References

May 29, 1992·Journal of Medicinal Chemistry·Z TomaszewskiD E Nichols
Apr 3, 1992·Journal of Medicinal Chemistry·J W EllinboeM L McCaleb
Jun 6, 1995·Proceedings of the National Academy of Sciences of the United States of America·G L WangG L Semenza
May 1, 1997·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·K M MalindaH K Kleinman
Mar 24, 1998·Annual Review of Medicine·B R Zetter
Dec 10, 1998·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·L SantanaE Cano
May 26, 1999·Journal of the National Cancer Institute·N J Nelson
Aug 18, 1999·Bioorganic & Medicinal Chemistry Letters·T K VinhC Simons
Sep 23, 2000·Nature·P Carmeliet, R K Jain
Jul 10, 2001·High Altitude Medicine & Biology·J Caro
Mar 22, 2002·The Lancet Oncology·D M Parkin
Apr 24, 2002·Oncogene·Mark A FeitelsonZhaorui Lian
Sep 18, 2003·Bioorganic & Medicinal Chemistry·Miyako MasubuchiNobuo Shimma
Mar 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michelangelo FiorentinoAntonia D'Errico-Grigioni
Jun 5, 2004·Bioorganic & Medicinal Chemistry Letters·Ichiro HayakawaYuichi Sugano
Jun 16, 2004·European Journal of Gastroenterology & Hepatology·Nathalie Ganne-Carrié, Jean-Claude Trinchet
Jun 29, 2007·Nature Clinical Practice. Oncology·Myron SchwartzManousos Konstadoulakis
Aug 30, 2008·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Hong-May SimMei-Lin Go
Nov 28, 2008·Bioorganic & Medicinal Chemistry Letters·Lidia S KonstantinovaOleg A Rakitin
Jun 6, 2009·Expert Review of Anticancer Therapy·Lorenza Rimassa, Armando Santoro
May 14, 2010·Journal of Medicinal Chemistry·Shudong WangPeter M Fischer
Jul 8, 2010·European Journal of Medicinal Chemistry·Samir BondockMohamed A Metwally

❮ Previous
Next ❯

Citations

Dec 25, 2019·IUBMB Life·Maryam ChamaniZatollah Asemi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.